{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:56:09Z","timestamp":1781978169035,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"crossref","award":["14\/527"],"award-info":[{"award-number":["14\/527"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>High body mass index (BMI) is strongly associated with hyperuricaemia. It is unknown whether overweight and obesity influences serum urate primarily through increased urate production or reduced renal clearance of uric acid. The aim of this study was to determine the influence of BMI on the response to inosine, a purine nucleoside that functions as an intermediate in the purine salvage and degradation pathways.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Following an overnight fast, 100 healthy participants without gout attended a study visit. Blood and urine samples were taken prior to and over 180\u2009min after 1.5\u2009g oral inosine. Serum urate and fractional excretion of uric acid (FEUA) were analysed according to high BMI (\u2265\u200925\u2009kg\/m<jats:sup>2<\/jats:sup>) and low\/normal BMI (&lt;\u200925\u2009kg\/m<jats:sup>2<\/jats:sup>) groups, and according to BMI as a continuous variable.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Participants in the high BMI group (<jats:italic>n<\/jats:italic>\u2009=\u200952, mean BMI 30.8\u2009kg\/m<jats:sup>2<\/jats:sup>) had higher serum urate concentrations at baseline (<jats:italic>P<\/jats:italic>\u2009=\u20090.002) compared to those with low\/normal BMI (mean BMI 21.8\u2009kg\/m<jats:sup>2<\/jats:sup>). However, the high BMI group had a smaller increase in serum urate following the inosine load (<jats:italic>P<\/jats:italic>\u2009=\u20090.0012). The two BMI groups had a similar FEUA at baseline (<jats:italic>P<\/jats:italic>\u2009=\u20090.995), but those in the high BMI group had a smaller increase in FEUA following the inosine (<jats:italic>P<\/jats:italic>\u2009=\u20090.0003). Similar findings were observed when analysing BMI as a continuous variable. Those with high BMI had a smaller increase in FEUA per increase in serum urate, compared to those with low BMI (<jats:italic>P<\/jats:italic>\u2009=\u20090.005).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In a fasting state, people with high BMI have elevated serum urate levels but similar FEUA values compared with those with low\/normal BMI. Following a purine load, those with high BMI have an attenuated renal excretion of uric acid. These data, using an experimental method to dynamically assess human urate handling, suggest that people with high BMI have a higher renal capacity for uric acid reabsorption when fasted and following a dietary purine intake have reduced renal clearance.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Australia and New Zealand Clinical Trials Registry, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=369688\">ACTRN12615001302549<\/jats:ext-link>, date of registration 30 November 2015.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-02357-y","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T09:08:39Z","timestamp":1604480919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of body mass index on serum urate and renal uric acid handling responses to an oral inosine load: experimental intervention study in healthy volunteers"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4476","authenticated-orcid":false,"given":"Nicola","family":"Dalbeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordyn","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen M.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony R.","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"2357_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/art.41067","volume":"72","author":"HK Choi","year":"2020","unstructured":"Choi HK, McCormick N, Lu N, Rai SK, Yokose C, Zhang Y. Population impact attributable to modifiable risk factors for hyperuricemia. Arthritis Rheumatol. 2020;72:157\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"2357_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1053\/meta.2001.24196","volume":"50","author":"N Nakanishi","year":"2001","unstructured":"Nakanishi N, Yoshida H, Nakamura K, Suzuki K, Tatara K. Predictors for development of hyperuricemia: an 8-year longitudinal study in middle-aged Japanese men. Metabolism. 2001;50:621\u20136.","journal-title":"Metabolism"},{"key":"2357_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1093\/rheumatology\/keq256","volume":"49","author":"Y Zhu","year":"2010","unstructured":"Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford). 2010;49:2391\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"2357_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","volume":"71","author":"MA Schwarzschild","year":"2014","unstructured":"Parkinson Study Group S-PDI, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71:141\u201350.","journal-title":"JAMA Neurol"},{"key":"2357_CR5","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/s41467-020-16525-w","volume":"11","author":"KM Hoque","year":"2020","unstructured":"Hoque KM, Dixon EE, Lewis RM, Allan J, Gamble GD, Phipps-Green AJ, et al. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. Nat Commun. 2020;11:2767.","journal-title":"Nat Commun"},{"key":"2357_CR6","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1136\/annrheumdis-2012-202732","volume":"72","author":"N Dalbeth","year":"2013","unstructured":"Dalbeth N, House ME, Gamble GD, Horne A, Pool B, Purvis L, et al. Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis. 2013;72:1868\u201373.","journal-title":"Ann Rheum Dis"},{"key":"2357_CR7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1136\/ard.2009.124230","volume":"69","author":"N Dalbeth","year":"2010","unstructured":"Dalbeth N, Wong S, Gamble GD, Horne A, Mason B, Pool B, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010;69:1677\u201382.","journal-title":"Ann Rheum Dis"},{"key":"2357_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000424","volume":"3","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Allan J, Gamble GD, Phipps-Green A, Flynn TJ, Mihov B, et al. Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study. RMD Open. 2017;3:e000424.","journal-title":"RMD Open"},{"key":"2357_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13075-015-0781-4","volume":"17","author":"N Dalbeth","year":"2015","unstructured":"Dalbeth N, Phipps-Green A, House ME, Gamble GD, Horne A, Stamp LK, et al. Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout. Arthritis Res Ther. 2015;17:263.","journal-title":"Arthritis Res Ther"},{"key":"2357_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/rheumatology\/ker361","volume":"51","author":"D Winnard","year":"2012","unstructured":"Winnard D, Wright C, Taylor WJ, Jackson G, Te Karu L, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51:901\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"2357_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1089\/acm.2008.0513","volume":"15","author":"CE Markowitz","year":"2009","unstructured":"Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, et al. The treatment of multiple sclerosis with inosine. J Altern Complement Med. 2009;15:619\u201325.","journal-title":"J Altern Complement Med"},{"key":"2357_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ajhg.2008.11.001","volume":"83","author":"H Matsuo","year":"2008","unstructured":"Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008;83:744\u201351.","journal-title":"Am J Hum Genet"},{"key":"2357_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/rheumatology\/ken066","volume":"47","author":"HK Choi","year":"2008","unstructured":"Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford). 2008;47:713\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"2357_CR14","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1001\/jama.1991.03470210076036","volume":"266","author":"F Facchini","year":"1991","unstructured":"Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008\u201311.","journal-title":"JAMA"},{"key":"2357_CR15","first-page":"E1","volume":"268","author":"A Quinones Galvan","year":"1995","unstructured":"Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, et al. Effect of insulin on uric acid excretion in humans. Am J Phys. 1995;268:E1\u20135.","journal-title":"Am J Phys"},{"key":"2357_CR16","first-page":"25","volume":"78","author":"H Vuorinen-Markkola","year":"1994","unstructured":"Vuorinen-Markkola H, Yki-J\u00e4rvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2357_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447\u201352.","journal-title":"Nature"},{"key":"2357_CR18","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1080\/15257770.2011.603711","volume":"30","author":"M Doshi","year":"2011","unstructured":"Doshi M, Takiue Y, Saito H, Hosoyamada M. The increased protein level of URAT1 was observed in obesity\/metabolic syndrome model mice. Nucleosides Nucleotides Nucleic Acids. 2011;30:1290\u20134.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2357_CR19","doi-asserted-by":"publisher","first-page":"F826","DOI":"10.1152\/ajprenal.00012.2017","volume":"313","author":"D Toyoki","year":"2017","unstructured":"Toyoki D, Shibata S, Kuribayashi-Okuma E, Xu N, Ishizawa K, Hosoyamada M, et al. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. Am J Physiol Renal Physiol. 2017;313:F826\u201334.","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02357-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-02357-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02357-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T01:04:12Z","timestamp":1604624652000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02357-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2357"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02357-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"4 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the New Zealand Health and Disability Ethics Committee (MEC\/05\/10\/130), and each participant gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ND reports grants and personal fees from AstraZeneca, grants from Amgen, and personal fees from Dyve Biosciences, Selecta, Hengrui, Horizon, Abbvie, Pfizer, Janssen, and Arthrosi, outside the submitted work. The other authors have no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"259"}}